Abstract: The present invention relates generally to the field of using udenafil or a pharmaceutically acceptable salt thereof in patients who have undergone the Fontan operation.
Type:
Grant
Filed:
February 2, 2018
Date of Patent:
May 19, 2020
Assignees:
Mezzion Pharma Co., Ltd., The Children's Hospital of Philadelphia
Inventors:
James L. Yeager, David J. Goldberg, Stephen M. Paridon
Abstract: The present invention relates generally to the field of using udenafil or a pharmaceutically acceptable salt thereof in patients who have undergone the Fontan operation.
Type:
Application
Filed:
September 28, 2018
Publication date:
January 31, 2019
Applicants:
Mezzion Pharma Co., Ltd., The Children's Hospital of Philadelphia, The Children's Hospital of Philadelphia
Inventors:
James L. Yeager, David J. Goldberg, Stephen M. Paridon
Abstract: The present invention relates generally to the field of using udenafil or a pharmaceutically acceptable salt thereof in patients who have undergone the Fontan operation.
Type:
Grant
Filed:
June 30, 2015
Date of Patent:
November 27, 2018
Assignees:
Mezzion Pharma Co., Ltd., The Children's Hospital of Philadelphia
Inventors:
James L. Yeager, David J. Goldberg, Stephen M. Paridon
Abstract: The present invention relates generally to the field of using udenafil or a pharmaceutically acceptable salt thereof in patients who have undergone the Fontan operation.
Abstract: The present invention relates to the pharmaceutical composition for prevention and treatment of liver diseases containing pyrazolopyrimidine derivative as an active ingredient. According to the present invention, pyrazolopyrimidine derivative has an excellent effect on inhibiting collagen synthesis in hepatic stellate cells and acts directly on the portal vein. Particularly, it may increase the diameter and the amount of blood flow of the portal vein, and finally decrease the pressure thereof. Therefore, pyrazolopyrimidine derivative can be used advantageously for prevention and treatment of hepatic fibrosis, liver cirrhosis caused by hepatic fibrosis, portal hypertension and various complications caused by portal hypertension. In addition, pyrazolopyrimidine derivative according to the present invention can reduce dosing frequency because of its long half-life, and therefore, has an advantage to improve the drug compliance of patients suffering from chronical liver diseases.